Zhengda Tianqing Pharmaceutical Group Co., Ltd. was founded in 1997. It is a high-tech enterprise, a large domestic liver health drug research and development and production base, and a large pharmaceutical enterprise integrating scientific research, production and sales.

Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and is a domestic liver health drug research and development and production base.

Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for corporate development and is one of the pharmaceutical companies that have invested a lot in innovative drug research in China. With the development of enterprises and the improvement of R&D capabilities, Zhengda Tianqing's R&D expenses have exceeded 1 billion yuan per year, and will gradually follow multinational companies. At present, the institute has 247 projects under development, including 31 new drugs in Class I and 32 biological drugs.

Zhengda Tianqing has built three production bases in Lianyungang, covering a total area of ​​more than 800 mu, including an incubation base covering an area of ​​160 mu, a raw material medicine base covering an area of ​​more than 200 mu, and a preparation base covering an area of ​​480 mu. The Zhengda Tianqing Preparation Base is designed and built in accordance with the EU and US FDA standards. Small-capacity injections have obtained the first GMP certificate in the country, and oral solid preparations have obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU-recognized GMP certification certificate issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major flagship products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market.

The treatment field of Zhengda Tianqing’s product involves various diseases such as liver disease, tumors, respiratory, infection, digestion, etc. 14 products with annual sales of over 100 million yuan have formed a "billion yuan product group", including two products with annual sales of over 2 billion yuan, namely the national first-class new drug isoglycidyl injection (Tianqing Ganmei) and the early domestic entecavir dispersed tablets (Runzhong). In addition to the field of strong liver disease, the anti-tumor field has also formed a unique product line. The hematologic tumor products decitabine, imatinib and dasatinib are the first domestic imitation; the solid tumor product capecitabine has been approved for marketing. Respiratory, antibiotics, endocrine and other fields will also be the direction of future development of enterprises.

In the future development, Zhengda Tianqing Pharmaceutical will continue to strengthen the construction of core competitiveness, establish and improve a scientific R&D system, so that the company's R&D level will always be in line with the international frontier.